Last updated: July 29, 2021
Sponsor: Grupo de Investigación Clínica en Oncología Radioterapia
Overall Status: Active - Recruiting
Phase
N/A
Condition
Heartburn
Esophageal Disorders
Heartburn (Pediatric)
Treatment
N/AClinical Study ID
NCT04070677
ZESRAD
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- ECOG PS 0-1.
- Signature of informed consent.
- Patients with any type of neoplasm that requires treatment with radiotherapy orradiochemotherapy, and who develop a radiation-induced esophagitis of degree ≥ 2 (according to CTCAE v4.03)
- Hematological function (neutrophils ≥2000 / ml, platelets ≥100000 / ml, hemoglobin> gr / dl), hepatic (bilirubin <1.5) and renal acceptable (glomerular filtration rate> 50ml / min).
- Patients without contraindication for the administration of ZIVEREL®, in accordancewith the instructions for use of the product.
Exclusion
Exclusion Criteria:
- ECOGPS≥2
- Hypersensitivity for some of the active ingredients or a component of ZIVEREL®
- Alteration in haematological function (neutrophils ≤2000 / ml, platelets ≤100000 / ml,hemoglobin <8gr/dl), hepatic (bilirubin> 1.5) and/or glomerular filtration rate <50ml/min).
- Patients who have a medical history of psychiatric disorders or any other conditionthat interfere with the study
- Patients with esophageal candidiasis or oral cavity candidiasis at the time of entryinto the study.
Study Design
Total Participants: 200
Study Start date:
June 15, 2019
Estimated Completion Date:
June 30, 2023
Study Description
Connect with a study center
Hospital Universitario Ramón y Cajal
Madrid, 28034
SpainActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.